This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

T-cell ALL and B-cell ALL

Authoring team

T-cell ALL:

  • complete remission rates have improved from about 40% to a range of 80-90%, and survival rates to 40-50% over the last 10 years
  • improved treatment success is believed to be the result of the inclusion of particular cytostatic drugs with activity against T lymphoblasts, e.g. cytarabine and cyclophosphamide

B-cell ALL:

  • the rate of complete remission has improved from 40% to 70%. The rate of disease-free survival has increased to 70+% in children and 40-50% in adults
  • improved treatment success is the result of inclusion in chemotherapy of high doses of cyclophosphamide, methotrexate, or cytarabine

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.